Read original
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify®, at the Norwegian University of Life Sciences (NMBU) in Ås. The pilot, which will be conducted in collaboration with the Faculty of Veterinary Medicine and Biosciences, specifically the Department of Companion Animal Clinical Sciences, aims to evaluate the effectiveness and potential integration of LAMPlify® within the university’s equine hospital.
The veterinary team at NMBU, led by Associate Professor Ingunn Risnes Hellings, will test LAMPlify® in their animal hospital laboratory. As a leading teaching and commercial hospital, the equine department treats horses from across Norway, and this pilot will explore the feasibility of adopting LAMPlify® as a vital tool for rapid, on-site diagnostics in their medicine department.
The pilot test will provide crucial insights into whether LAMPlify® can meet the hospital’s needs for efficient, point-of-care diagnostics, potentially transforming the way they manage and treat equine patients.
“We’re excited to see the growing interest in Diagonal Bio beyond Sweden. With partnerships already established in Denmark, it’s clear that the demand for fast, accurate diagnostics is spreading, and we are proud to support improved veterinary care internationally. Further, I see this collaboration with the Norwegian University of Life Sciences as a great opportunity to see how LAMPlify® can improve diagnostic speed and accuracy in a busy veterinary setting.”- Karin Wehlin, CEO of Diagonal Bio AB (publ)
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 25, 2024, at 14:15 CET.
For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.
